What is the current stock price of PepGen Inc. (PEPG)?

As of the latest market data, PepGen Inc. (PEPG) is trading at $1.64. The stock has seen a gain of 1.86% today.

Does PepGen Inc. (PEPG) pay a dividend?

Based on current data, PepGen Inc. does not have a confirmed active dividend policy.

What is the market cap of PepGen Inc.?

The current market capitalization of PepGen Inc. (PEPG) is approximately unavailable.

PEPG

PepGen Inc.·Healthcare

1.64

1.863%(+0.03)

Market Closed

1.69

3.049%(+0.05)

After Hours

Last Updated: — ET

52W L: $1.0152W H: $7.80

PEPG NEWS

prnewswire.com

2d ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

globenewswire.com

3d ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

prnewswire.com

Apr 2

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

prnewswire.com

Apr 2

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

globenewswire.com

Mar 31

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

globenewswire.com

Mar 31

PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of PepGen Inc. (NASDAQ: PEPG). The investigation focuses on whether PepGen or certain of its executives violated federal securities laws.

Company Profile

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2022-05-06

Beta

2.34

Websitewww.pepgen.com↗